Today: 18 July 2026
Browse Category

Biotechnology 22 June 2025 - 26 September 2025

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective Sept. 15. The deal potentially opens access to more than 51 million members nationwide and positions CNSide as a covered testing service for specialists treating leptomeningeal metastases—a devastating complication of advanced cancers. GlobeNewswire
26 September 2025
···
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure’s stock performance in 2025 has been remarkably strong, capped by the explosive move on Sep. 24 after the Huntington’s data release. Prior to the announcement, QURE was trading in the mid-teens ts2.tech – already up over 100% year-to-date as anticipation for the trial results built. When the pivotal results hit, trading was halted pre-market due to pending news ts2.tech. Once the halt lifted, the stock opened dramatically higher and at one point reached the mid-$40s per share, up nearly 160–200% in a single session pharmaphorum.com. It eventually closed with a gain of around 150%+ on the day investing.com. This massive one-day jump is one of the biotech sector’s biggest of 2025, reflecting how transformational the news was for uniQure’s outlook.
24 September 2025
····
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Historic Huntington’s Results: On September 24, 2025, uniQure revealed landmark Phase I/II trial results for its Huntington’s disease gene therapy AMT-130. In patients treated with a one-time injection of AMT-130, disease progression was significantly slowed – by about 75% over three years for those on the high dose reuters.com. Treated patients maintained far more of their motor and cognitive function compared to the expected decline in Huntington’s, which is an invariably progressive and fatal neurodegenerative disorder reuters.com reuters.com. Crucially, there are currently no approved drugs that slow Huntington’s disease, so these results position AMT-130 as potentially the first disease-modifying therapy in this space reuters.com.
24 September 2025
···
Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Lyme disease is often called a “plague” on Nantucket. The tiny Massachusetts island, famed for its beaches, has one of the nation’s highest infection rates media.mit.edu. About 15% of Nantucket’s residents have contracted Lyme disease, which causes fevers, rashes, swollen joints, and even nerve damage cbsnews.com cbsnews.com. The culprit is a spiral-shaped bacteria spread by black-legged ticks, commonly known as deer ticks. But while deer and ticks get most of the blame, scientists point to a different host at the heart of Lyme’s spread: the white-footed mouse cbsnews.com.
23 September 2025
CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Phenylketonuria is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid nature.com fiercebiotech.com. Without a working PAH enzyme, phenylalanine builds up to toxic levels, causing brain damage, intellectual disability, and seizures if untreated. Newborn screening identifies PKU early, and patients are put on a strict lifetime diet limiting protein pennmedicine.org fiercebiotech.com. Even with dietary control and medications, many patients struggle – foods high in protein are largely off-limits, and even newer drugs like sapropterin only help certain mutations nature.com fiercebiotech.com. In short, PKU remains a lifelong burden, fueling the search for a one-time genetic cure.
15 September 2025
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com.
28 August 2025
····
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Sources: Key information in this report is drawn from reputable industry and news outlets including Reuters reuters.com reuters.com, Fierce Biotech/Pharma fiercebiotech.com fiercebiotech.com, Endpoints News, STAT, and official statements from organizations like the FDA, EMA, WHO, and leading medical journals. For full details and additional context, please refer to the cited sources inline.
20 August 2025
·····
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Sources: Key news and expert quotes were gathered from Fierce Biotech fiercebiotech.com fiercebiotech.com, Fierce Pharma fiercepharma.com fiercepharma.com, Fierce Healthcare fiercehealthcare.com fiercehealthcare.com, STAT News statnews.com statnews.com, the Florida Phoenix floridaphoenix.com floridaphoenix.com, CIDRAP cidrap.umn.edu cidrap.umn.edu, and other authoritative sources as cited above. Each development is linked to its original reporting for further reading. The roundup covers events and announcements from August 18–19, 2025, providing a comprehensive digest of the latest in biotech, pharma, medical, and health news.
19 August 2025
····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links:
16 August 2025
··········
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The first half of 2025 has seen biotechnology and health technology sectors accelerate on multiple fronts, from groundbreaking scientific advances to robust deal-making. Industry optimism is high – a Deloitte survey of 150 life science executives found 75% believe 2025 will be a strong year, citing anticipated revenue growth and rapid innovation genengnews.com. This optimism is translating into action, with emerging technologies like gene editing, precision medicine, digital health, and AI reaching new milestones. Meanwhile, global market projections remain bullish: for example, the AI in healthcare market is projected to grow about 10-fold from ~$15 billion in 2024 to over $164 billion by 2030 globenewswire.com, and the digital health market is expected to soar past $1 trillion by the early 2030s precedenceresearch.com.
27 June 2025
···········
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Biotechnology is at the forefront of scientific innovation in 2025, driven by companies around the world that are transforming healthcare, agriculture, and industry. This report profiles 100 of the most important global biotechnology companies selected for their global impact, innovation, revenue, scientific breakthroughs, and sector influence. These companies span biopharmaceutical giants, genomics and diagnostics pioneers, agricultural and environmental biotech leaders, industrial biotech innovators, and key providers of biotech tools and services. Each entry includes the company’s headquarters country, primary sector, notable contributions or innovations, and a link to its official website. The list encompasses both publicly traded and private firms, reflecting the worldwide landscape of biotech innovation.
22 June 2025
···········
1 … 17 18 19
Go toTop